CD3

Runimotamab (BTRC-4017A) is a HER2 and CD3 T cell-engaging bispecific antibody.

Anti-CD3 Antibody (OKT-3) is a kind of mouse IgG2a κ antibody inhibitor, targeting to human CD3.

Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a K d of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti- CD3 single-chain variable fragment ( scFv ) domain, and to STEAP1 via a bispecific anti- STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1 -expressing cancer cells.

Duvortuxizumab (MGD 011) is a chimeric humanized IG antibody targeting CD19 and CD3E [1] .

Anti-Mouse CD3ε Antibody (KT3) is a rat-derived IgG2a type antibody inhibitor, targeting to mouse CD3ε. Anti-Mouse CD3ε Antibody (KT3) increases thymocytes proliferation.

Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized, IgG1-based bispecific antibody that targets the near-membrane extracellular domain of FcRH5 on multiple myeloma (MM) cells and CD3 on T cells. Additionally, Cevostamab promotes effective synapse formation, enhancing T cell killing activity against MM tumor cells.

Foralumab (NI-0401) is an orally effective humanized monoclonal antibody that targets CD3. Foralumab can modulate the immune response of human cells reconstructed from hematopoietic stem cells in NSG mice.

Muromonab is a monoclonal antibody that targets the CD3 receptor. It can block all cytotoxic T cell functions. Muromonab is also used as an immunosuppressant to reduce acute solid organ transplant rejection reactions.

Talquetamab (JNJ-64407564) is a humanized bispecific antibody that can bind to both GPRC5D (a member of the G protein-coupled receptor family C5) and CD3, inducing T cell-mediated killing of MM cells expressing GPRC5 through recruitment and activation of T cells. Talquetamab (JNJ-64407564) has anti-tumor activity.

Teplizumab (MGA-031) is a monoclonal antibody that targets human CD3 and is of the Fc receptor type, non-binding subtype. Teplizumab can alleviate the loss of function in beta cells and is used for research on type 1 diabetes.

Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes.

Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA).

Vonsetamig is a humanised immunoglobulin G4-kappa, anti-TNFRSF17 and CD3E monoclonal antibody.

Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells.

Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells.

Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis.

Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody that binds PSMA and CD3 and has anti-cancer activity for use in prostate cancer research.

Vibecotamab (XmAb14045) is a potent bispecific antibody against CD123 and CD3 that stimulates T cell-mediated targeted killing of CD123-expressing cells.

Vepsitamab (AMG 199) is an anti-MUC17/CD3 BiTE antibody that binds to CD3 on T cells and MUC17 expressed on tumor cells, mediates redirected tumor cell lysis, and induces T cell activation and proliferation.

Ubamatamab (REGN4018) is a humanized bispecific antibody targeted against Mucin 16 (MUC16) and CD3.

Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors.

Solitomab (AMG 110) is a bispecific anti-CD3 and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody.

Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule.

Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody.